Genentech obesity drugs post Phase II weight-loss data
See more from StockTitan in…
Roche obesity drugs post Phase II weight-loss data
Roche (OTCQX:RHHBY) will present new Phase II data from its obesity portfolio at…
RHHBY’s Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER | News
Swiss pharma giant Roche Holding AG’s RHHBY first-quarter 2026 results were affected by currency headwinds. Sales totaled $18.8…
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to…
Genentech petrelintide sheds 10.7% weight in Phase II
03/05/2026 – 01:45 PM – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus…
Roche’s Weight-Loss Ambitions Face Reality Check
Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…
Roche, Zealand’s amylin weight loss drug fails to clear Lilly’s bar
Yet another potential weight loss competitor has fallen short of defending champion Eli Lilly’s rival candidate in the…
Roche Phase II weight-loss drug trims 10.7% vs placebo
Roche (OTCQX: RHHBY) reported positive Phase II ZUPREME-1 topline results for petrelintide, an…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the…